These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

461 related items for PubMed ID: 2309110

  • 1. [The treatment of anemia of hemodialysis patients using recombinant human erythropoietin: comparison between intravenous and subcutaneous administration].
    Zehnder C, Blumberg A.
    Schweiz Med Wochenschr; 1990 Feb 17; 120(7):217-20. PubMed ID: 2309110
    [Abstract] [Full Text] [Related]

  • 2. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
    Martínez Castelao A, Reyes A, Valdés F, Otero A, López de Novales E, Pallardó L, Tabernero JM, Hernández Jaras J, Lladós F.
    Nefrologia; 2003 Feb 17; 23(2):114-24. PubMed ID: 12778875
    [Abstract] [Full Text] [Related]

  • 3. [Comparison of the efficacy and tolerance of recombinant human erythropoietin between intravenous and subcutaneous administration in chronic hemodialysis. Prospective multicenter study].
    Ruedin P, Stoerman C, Pechère-Bertschi A, Leski M.
    Nephrologie; 1992 Feb 17; 13(2):87-92. PubMed ID: 1608502
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and tolerance of treatment with recombinant-human erythropoietin in chronic renal failure (pre-dialysis) patients.
    Frenken LA, Verberckmoes R, Michielsen P, Koene RA.
    Nephrol Dial Transplant; 1989 Feb 17; 4(9):782-6. PubMed ID: 2516609
    [Abstract] [Full Text] [Related]

  • 5. Proposed therapeutic algorithm for the treatment of anemia of chronic renal failure in pre-dialysis patients with low dose once weekly subcutaneous r-HuEPO. Multicenter Study Group, Israel.
    Yagil Y.
    Isr J Med Sci; 1997 Jan 17; 33(1):36-44. PubMed ID: 9203516
    [Abstract] [Full Text] [Related]

  • 6. Erythropoietin dose requirements when converting from subcutaneous to intravenous administration among patients on hemodialysis.
    Moist LM, Muirhead N, Wazny LD, Gallo KL, Heidenheim AP, House AA.
    Ann Pharmacother; 2006 Feb 17; 40(2):198-203. PubMed ID: 16449549
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A, Salifu MO, Lunde NM, Bansal V, Fishbane S, Dougherty FC, Beyer U, Ba16285 Study Investigators.
    Clin Ther; 2007 Apr 17; 29(4):626-39. PubMed ID: 17617286
    [Abstract] [Full Text] [Related]

  • 8. [Recombinant human erythropoietin: 18 months of continuous use in substitution hemodialysis].
    Canaud B, Polito-Bouloux C, Rivory JP, Donnadieu P, Taib J, Florence P, Mion C.
    Nephrologie; 1990 Apr 17; 11(1):5-10. PubMed ID: 2374643
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis.
    Lui SF, Law CB, Ting SM, Li P, Lai KN.
    Clin Nephrol; 1991 Nov 17; 36(5):246-51. PubMed ID: 1752075
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Successful treatment of anemia in hemolysis patients using recombinant human erythropoietin. Maintenance dosage and serum concentration].
    Stutz B, Rhyner K, Vögtli J, Binswanger U.
    Schweiz Med Wochenschr; 1987 Sep 19; 117(38):1397-402. PubMed ID: 3672079
    [Abstract] [Full Text] [Related]

  • 14. Erythropoietin-alpha dosage requirements in a provincial hemodialysis population: effect of switching from subcutaneous to intravenous administration.
    Raymond CB, Collins DM, Bernstein KN, Skwarchuk DE, Vercaigne LM.
    Nephron Clin Pract; 2006 Sep 19; 102(3-4):c88-92. PubMed ID: 16282700
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [The treatment of anemia in patients on hemodialysis with recombinant human erythropoietin].
    Borrego FJ, Miguel JL, Zamorano A, Muñoz J, Bajo A, López-Revuelta K, Sánchez Sicilia L.
    Med Clin (Barc); 1991 Nov 23; 97(18):687-92. PubMed ID: 1770818
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Recombinant human erythropoietin treatment: investigational new drug protocol for the anemia of the acquired immunodeficiency syndrome. Overall results.
    Phair JP, Abels RI, McNeill MV, Sullivan DJ.
    Arch Intern Med; 1993 Dec 13; 153(23):2669-75. PubMed ID: 8250662
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.